Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A

Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions MISSISSAUGA, ON,(Healthcare Sales & Marketing Network) - Today Biogen Idec (BIIB) announces that Health Canad... Biopharmaceuticals, RegulatoryBiogen Idec, ELOCTATE, Antihemophilic Factor, hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news